Can a smart drug deliver a toxic payload directly to cancer cells?

NCT ID NCT07726212

Not yet recruiting Disease control Sponsor: Hangzhou MacroLink Biopharmaceutical LLC Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This early-phase trial is testing an experimental antibody-drug conjugate called MC002 in adults with advanced solid tumors, such as esophageal or lung cancer, that have progressed after standard treatments. MC002 is designed to target a protein found on cancer cells and deliver a chemotherapy-like payload directly to them. The study aims to find a safe dose and see whether the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an antibody-drug conjugate called MC002 that targets a protein found on cancer cells
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, first-in-human trial, so the drug may not be safe or effective. Side effects from the antibody-drug conjugate could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer lung cancer lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED ESOPHAGEAL CANCER ADVANCED LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.